Retatrutide 5mg 10mg 15mg 30mg Lyophilized Peptide Powder for Weight Loss Research | CAS 2381089-83-2

Retatrutide/">Retatrutide/">Retatrutide/">Retatrutide/">Retatrutide/">Retatrutide/">Retatrutide is a novel triple agonist peptide that simultaneously targets the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR) and glucagon-like peptide-1 receptor (GLP-1R). This unique mechanism makes it particularly effective for metabolic research applications.

The peptide demonstrates potent activity with EC50 values of 5.79 nM for human GCGR, 0.0643 nM for human GIPR, and 0.775 nM for human GLP-1R. In mouse models, it shows EC50 values of 2.32 nM (GCGR), 0.191 nM (GIPR), and 0.794 nM (GLP-1R).

Retatrutide functions by activating the GLP-1R signaling pathway to stimulate glucose-dependent insulin secretion. It has shown significant effects in delaying gastric emptying, lowering both fasting and postprandial glucose concentrations, reducing food intake, and promoting weight loss in research models.

For research purposes, Retatrutide has demonstrated potential in improving renal function by reducing albuminuria levels and increasing renal filtration rate in diabetic models. These effects appear to be mediated through GLP-1R/GR-dependent signaling pathways that produce anti-inflammatory and antiapoptotic effects.

The lyophilized white powder is water soluble (5mg/ml) and should be stored at -20°C to maintain stability. Each vial contains high purity (>99%) peptide suitable for laboratory research applications.

Common research observations include gastrointestinal effects such as nausea, diarrhea, vomiting, and constipation at higher doses. These effects are typically dose-dependent and reversible.